Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec®, Glivec®, Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program (“Care club”, “Happy club” in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.
- Kantarjian H, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–52. CrossRef
- Talpaz M, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928–37. CrossRef
- Sawyers CL, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–9. CrossRef
- O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. CrossRef
- Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. CrossRef
- Kantarjian HM, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835–40. CrossRef
- Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004;9:259–70. CrossRef
- Kiguchi T, et al. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res. 2009;33:506–8. CrossRef
- Hochhaus A, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–6. CrossRef
- Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. CrossRef
- Sandoval C, Giamelli J, Jayabose S. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. J Pediatr Hematol Oncol. 2003;25:507–8. CrossRef
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97. CrossRef
- Moore S. Facilitating oral chemotherapy treatment and compliance through patient/family-focused education. Cancer Nurs. 2007;30:112–22. CrossRef
- Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66. CrossRef
- Noens L, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11. CrossRef
- Druker BJ, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. CrossRef
- Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol (ASCO Ann Meet Proc). 2006;24:6119.
- Baccarani M, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009;113:4497–504. CrossRef
- Bazeos A, et al. Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood (ASH Ann Meet Abst). 2009;114:3290.
- Darkow T, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–96. CrossRef
- Halpern P, et al. Relationship between compliance, costs, hospitalization for CML and GIST patients using imatinib mesylate. J Clin Oncol (ASCO Ann Meet Proc). 2008;26:6598.
- Henk HJ, et al. The impact of non-compliance with imatinib (IM) therapy on health care costs. J Clin Oncol (ASCO Ann Meet Proc). 2006;24:6083.
- Doti C, et al. Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study. Blood. 2007;110:4553.
- Cohen R, et al. Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc. 2009;12:23. CrossRef
- Levine AM, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469–76.
- Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients
Volume 29, Issue 2 , pp 1179-1185
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Chronic myeloid leukemia
- Patient counseling program
- Industry Sectors
- Author Affiliations
- 1. Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 200 Dongduk–Ro, Jung–Gu, Daegu, 700-721, Korea
- 2. Department of Hematology/Oncology, Seoul National University Hospital, Seoul, Korea
- 3. Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Gwangju, Korea
- 4. Department of Hematology/Oncology, Yonsei University Severance Hospital, Seoul, Korea
- 5. Department of Hematology/Oncology, Samsung Medical Center, Seoul, Korea